Raymond James Financial Inc. bought a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 26,143 shares of the company's stock, valued at approximately $533,000.
Other hedge funds have also modified their holdings of the company. Proficio Capital Partners LLC purchased a new position in Denali Therapeutics during the 4th quarter worth $514,000. JPMorgan Chase & Co. grew its stake in shares of Denali Therapeutics by 6.5% during the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock worth $6,857,000 after acquiring an additional 14,324 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock valued at $36,076,000 after acquiring an additional 149,939 shares in the last quarter. Barclays PLC increased its holdings in shares of Denali Therapeutics by 101.4% during the third quarter. Barclays PLC now owns 255,883 shares of the company's stock valued at $7,454,000 after acquiring an additional 128,823 shares in the last quarter. Finally, KBC Group NV raised its position in shares of Denali Therapeutics by 75.8% in the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after purchasing an additional 2,731 shares during the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.
Denali Therapeutics Stock Up 1.6 %
Shares of NASDAQ DNLI traded up $0.20 during trading on Friday, hitting $12.70. The company had a trading volume of 1,626,428 shares, compared to its average volume of 1,078,596. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of -4.60 and a beta of 1.58. The stock has a fifty day simple moving average of $16.53 and a two-hundred day simple moving average of $21.83. Denali Therapeutics Inc. has a fifty-two week low of $10.57 and a fifty-two week high of $33.33.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms have issued reports on DNLI. B. Riley reaffirmed a "buy" rating and issued a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Oppenheimer lowered their price target on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Robert W. Baird assumed coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price objective for the company. HC Wainwright lifted their price objective on shares of Denali Therapeutics from $80.00 to $87.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a report on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price objective for the company. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of "Buy" and an average price target of $37.57.
Read Our Latest Stock Report on DNLI
Denali Therapeutics Profile
(
Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Further Reading
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
